title: Gating strategy for immunophenotyping of leukemia and lymphoma.
abstract: Clinical specimens of blood, bone marrow, lymph node, extranodal tissue, and body fluid were collected from 67 cases of hematologic neoplasms (including chronic lymphoid leukemias, T- and B-cell lymphomas, and acute lymphoblastic and myelogenous leukemias) for comparison between the right-angle light scatter (RALS)/CD45 and the forward-angle light scatter (FALS)/RALS gating combinations. One to three diagnostic markers were selected from each case, yielding 124 paired results for comparison. We found that the percentage of tumor cell isolation and the total cell count in the tumor cell gate were higher in RALS/CD45 than in FALS/RALS. When 20% was used as a cutoff point, 30 markers in FALS/RALS failed to identify the tumor population, while only 3 markers in RALS/CD45 failed to do so. The discriminative factor in the RALS/CD45 gating was mainly the CD45 intensity, whereas all cases except 3 showed low RALS. Although T-cell neoplasms showed a higher proportion of high CD45 intensity, other groups shared similar ranges of CD45 intensity, which is therefore of limited value for differential diagnosis. The RALS/CD45 combination produces higher recovery and purity for tumor cell isolation than the FALS/RALS combination and should replace the latter for routine immunophenotyping of lymphoma and leukemia.
authors.affiliation: Veterans Affairs Medical Center, and the Department of Pathology, University of Colorado School of Medicine, Denver 80220, USA.
authors.forename: T
authors.initials: T
authors.lastname: Sun
authors.forename: R
authors.initials: R
authors.lastname: Sangaline
authors.forename: J
authors.initials: J
authors.lastname: Ryder
authors.forename: K
authors.initials: K
authors.lastname: Gibbens
authors.forename: C
authors.initials: C
authors.lastname: Rollo
authors.forename: S
authors.initials: S
authors.lastname: Stewart
authors.forename: C
authors.initials: C
authors.lastname: Rajagopalan
mesh_terms: D014408:Biomarkers, Tumor; D001853:Bone Marrow / Q000473:pathology; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D007938:Leukemia / Q000473:pathology*; D007945:Leukemia, Lymphoid / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology; D017493:Leukocyte Common Antigens / Q000032:analysis; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000473:pathology; D008223:Lymphoma / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D017493:Leukocyte Common Antigens